Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Followed by Chemoradiation for Locally-Advanced NSCLC
NCT05624996Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2023
- Primary completion
- Oct 2031
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NRG Oncology. Primary endpoints: Overall Survival up to 8 years and Progression-Free Survival up to 8 years. Started Jul 2023; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05624996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624996.